Näytä suppeat kuvailutiedot

dc.contributor.authorElomaa, Hanna
dc.contributor.authorAhtiainen, Maarit
dc.contributor.authorVäyrynen, Sara A.
dc.contributor.authorOgino, Shuji
dc.contributor.authorNowak, Jonathan A.
dc.contributor.authorLau, Mai Chan
dc.contributor.authorHelminen, Olli
dc.contributor.authorWirta, Erkki-Ville
dc.contributor.authorSeppälä, Toni T.
dc.contributor.authorBöhm, Jan
dc.contributor.authorMecklin, Jukka-Pekka
dc.contributor.authorKuopio, Teijo
dc.contributor.authorVäyrynen, Juha P.
dc.date.accessioned2023-04-06T09:09:58Z
dc.date.available2023-04-06T09:09:58Z
dc.date.issued2023
dc.identifier.citationElomaa, H., Ahtiainen, M., Väyrynen, S. A., Ogino, S., Nowak, J. A., Lau, M. C., Helminen, O., Wirta, E.-V., Seppälä, T. T., Böhm, J., Mecklin, J.-P., Kuopio, T., & Väyrynen, J. P. (2023). Spatially resolved multimarker evaluation of CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint expression and macrophage polarisation in colorectal cancer. <i>British Journal of Cancer</i>, <i>128</i>(11), 2104-2115. <a href="https://doi.org/10.1038/s41416-023-02238-6" target="_blank">https://doi.org/10.1038/s41416-023-02238-6</a>
dc.identifier.otherCONVID_182674730
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/86295
dc.description.abstractBackground The CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint interaction may promote cancer progression, but the expression patterns and prognostic significance of PD-L1 and PD-1 in the colorectal cancer microenvironment are inadequately characterised. Methods We used a custom 9-plex immunohistochemistry assay to quantify the expression patterns of PD-L1 and PD-1 in macrophages, T cells, and tumour cells in 910 colorectal cancer patients. We evaluated cancer-specific mortality according to immune cell subset densities using multivariable Cox regression models. Results Compared to PD-L1– macrophages, PD-L1+ macrophages were more likely M1-polarised than M2-polarised and located closer to tumour cells. PD-L1+ macrophage density in the invasive margin associated with longer cancer-specific survival [Ptrend = 0.0004, HR for the highest vs. lowest quartile, 0.52; 95% CI: 0.34–0.78]. T cell densities associated with longer cancer-specific survival regardless of PD-1 expression (Ptrend < 0.005 for both PD-1+ and PD-1– subsets). Higher densities of PD-1+ T cell/PD-L1+ macrophage clusters associated with longer cancer-specific survival (Ptrend < 0.005). Conclusions PD-L1+ macrophages show distinct polarisation profiles (more M1-like), spatial features (greater co-localisation with tumour cells and PD-1+ T cells), and associations with favourable clinical outcome. Our comprehensive multimarker assessment could enhance the understanding of immune checkpoints in the tumour microenvironment and promote the development of improved immunotherapies.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.ispartofseriesBritish Journal of Cancer
dc.rightsCC BY 4.0
dc.subject.othercancer microenvironment
dc.subject.othercolorectal cancer
dc.subject.otherprognostic markers
dc.subject.othertumour immunology
dc.titleSpatially resolved multimarker evaluation of CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint expression and macrophage polarisation in colorectal cancer
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202304062426
dc.contributor.laitosMatemaattis-luonnontieteellinen tiedekuntafi
dc.contributor.laitosBio- ja ympäristötieteiden laitosfi
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Mathematics and Scienceen
dc.contributor.laitosDepartment of Biological and Environmental Scienceen
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.oppiaineSolu- ja molekyylibiologiafi
dc.contributor.oppiaineCell and Molecular Biologyen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.format.pagerange2104-2115
dc.relation.issn0007-0920
dc.relation.numberinseries11
dc.relation.volume128
dc.type.versionpublishedVersion
dc.rights.copyright© The Author(s) 2023
dc.rights.accesslevelopenAccessfi
dc.subject.ysoimmunologia
dc.subject.ysosuolistosyövät
dc.subject.ysokasvaimet
dc.subject.ysoimmuunijärjestelmä
dc.subject.ysosyöpätaudit
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p18810
jyx.subject.urihttp://www.yso.fi/onto/yso/p25845
jyx.subject.urihttp://www.yso.fi/onto/yso/p2299
jyx.subject.urihttp://www.yso.fi/onto/yso/p16041
jyx.subject.urihttp://www.yso.fi/onto/yso/p678
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.1038/s41416-023-02238-6
jyx.fundinginformationThis study was funded by Cancer Foundation Finland (59-5619 to J.P. Väyrynen) and Emil Aaltonen Foundation (220022K to H. Elomaa). Open Access funding provided by University of Oulu including Oulu University Hospital.
dc.type.okmA1


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot

CC BY 4.0
Ellei muuten mainita, aineiston lisenssi on CC BY 4.0